Eterna Therapeutics
ERNA
#9227
Rank
A$85.01 M
Marketcap
$1.66
Share price
-5.26%
Change (1 day)
-8.39%
Change (1 year)

P/E ratio for Eterna Therapeutics (ERNA)

P/E ratio as of November 2024 (TTM): -0.1915

According to Eterna Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.191489. At the end of 2021 the company had a P/E ratio of -1.50.

P/E ratio history for Eterna Therapeutics from 2021 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2021-1.50

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
6.61-3,550.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-11.7 5,997.74%๐Ÿ‡บ๐Ÿ‡ธ USA
6.66-3,576.05%๐Ÿ‡บ๐Ÿ‡ธ USA
15.8-8,333.42%๐Ÿ‡ซ๐Ÿ‡ท France
47.4-24,850.72%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡ฆ๐Ÿ‡บ Australia
-8.56 4,367.62%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.